IMRX - Immuneering Corporation Latest News | Finranks

05.08.2026

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 - - Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date - - Peer-reviewed publication in Cancer Research details atebimetinib's broad, durable preclinical activity, and favorable tolerability across RAS- and RAF-mutant tumors, along with preservation of body mass - - Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 - NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the second quarter ended June 30, 2026, and provided business updates. “At a time when first-line pancreatic cancer patients finally have treatment options, the 17.3 month median overall survival reported at ASCO for atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in our single-arm Phase 2a study stands out as potentially best-in-class.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
IMRX	H.C. Wainwright	Buy	undefined >> $14	August 6th 2026

Press releases

05.08.2026

Immuneering Corporation (IMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immuneering Corporation (IMRX)

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Upgrades / Downgrades

Press releases

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Search stocks

Immuneering Corporation (IMRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immuneering Corporation (IMRX)

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Upgrades / Downgrades

Press releases

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates